SC79
目录号:S7863 Purity: 97%
SC79是一种大脑渗透性Akt磷酸化激活剂,也是一种Akt-PH域易位抑制剂。
CAS: 305834-79-1
客户使用Selleck的SC79发表文献149篇
- Signal Transduct Target Ther, 2024 9(1):109
- Mol Cancer, 2020 19(1):166
- J Hematol Oncol, 2020 13(1):11
- Nat Metab, 2019 1(8):765-774
- J Ethnopharmacol, 2025 339:119135
- J Exp Clin Cancer Res, 2024 43(1):56
- MedComm (2020), 2024 5(12):e70033
- Phytomedicine, 2024 133:155931
- Phytomedicine, 2024 155377
- Elife, 2024 13RP93087
- Elife, 2024 13e82809
- Genes Dis, 2024 11(2):964-977
- Hepatol Int, 2024 10.1007/s12072-024-10696-0
- iScience, 2024 27(5):109799
- Aging (Albany NY), 2024 16(19):12850-12865
- Sci Rep, 2024 14(1):19354
- Sci Rep, 2024 14(1):5038
- Cancer Med, 2024 13(16):e70100
- J Ovarian Res, 2024 17(1):44
- Acta Biochim Biophys Sin (Shanghai), 2024 56(7):1065-1071
- Acta Biochim Biophys Sin (Shanghai), 2024 56(5):776-788
- BMC Womens Health, 2024 24(1):25
- Nat Commun, 2023 14(1):5351
- Cell Death Dis, 2023 14(8):575
- Cell Death Dis, 2023 14(5):316
- Biomed Pharmacother, 2023 162:114654
- Free Radic Biol Med, 2023 202:35-45
- Commun Biol, 2023 6(1):680
- Burns Trauma, 2023 11:tkad003
- Chem Biol Interact, 2023 10.1016/j.cbi.2023.110725
- Drug Des Devel Ther, 2023 17:659-673
- J Cancer, 2023 14(8):1350-1361
- J Cancer, 2023 10.7150/jca.87545
- Neurosci Insights, 2023 18:26331055231186993
- Heliyon, 2023 9(8):e18954
- Theranostics, 2022 12(3):1148-1160
- Cancer Lett, 2022 543:215783
- Cell Mol Gastroenterol Hepatol, 2022 14(6):1311-1331
- Oncogenesis, 2022 11(1):58
- Am J Pathol, 2022 S0002-9440(22)00005-0
- Front Pharmacol, 2022 13:861319
- Front Pharmacol, 2022 13:890974
- J Ethnopharmacol, 2022 294:115342
- Int J Oncol, 2022 61(4)115
- Inflammation, 2022 10.1007/s10753-022-01762-6
- Front Oncol, 2022 12:744984
- Sci Rep, 2022 12(1):18509
- Invest Ophthalmol Vis Sci, 2022 63(8):23
- Oncol Rep, 2022 47(3)50
- Biochem Biophys Res Commun, 2022 613:53-60
- Mol Reprod Dev, 2022 10.1002/mrd.23569
- Theranostics, 2021 11(12):6006-6018
- J Biomed Sci, 2021 28(1):13
- Curr Biol, 2021 S0960-9822(21)00626-6
- Cell Death Dis, 2021 12(1):18
- Cell Death Dis, 2021 12(1):97
- Cell Biosci, 2021 11(1):124
- Oxid Med Cell Longev, 2021 2021:9911537
- Cancer Cell Int, 2021 21(1):662
- Cancer Sci, 2021 10.1111/cas.14988
- Front Pharmacol, 2021 12:659511
- Front Pharmacol, 2021 12:594833
- Front Cell Dev Biol, 2021 9:645658
- Front Cell Neurosci, 2021 15:679413
- J Cell Mol Med, 2021 25(7):3182-3193
- Front Mol Biosci, 2021 8:789658
- FASEB J, 2021 35(3):e21263
- Front Oncol, 2021 11:682773
- Molecules, 2021 26(4)781
- J Oncol, 2021 2021:1406853
- Oncol Rep, 2021 45(4):1
- J Cancer, 2021 12(19):5903-5913
- Acta Biochim Biophys Sin (Shanghai), 2021 gmab026
- Ann Anat, 2021 240:151885
- Adv Sci (Weinh), 2020 7(13):2000112
- Biomaterials, 2020 237:119793
- Proc Natl Acad Sci U S A, 2020 117(40):25104-25115
- Cell Death Dis, 2020 11(9):752
- Cell Death Dis, 2020 11(9):755
- Cell Death Dis, 2020 14;11(4):230
- Br J Cancer, 2020 10.1038/s41416-020-1007-3
- Cell Rep, 2020 30(5):1400-1416
- Diabetologia, 2020 10.1007/s00125-020-05299-x
- Front Immunol, 2020 11:581673
- Life Sci, 2020 250:117546
- Cells, 2020 9(1)
- Cancer Cell Int, 2020 27;20:198
- Int J Mol Med, 2020 10.3892/ijmm.2020.4788
- Front Microbiol, 2020 11:565590
- Front Oncol, 2020 10:1508
- Front Oncol, 2020 11;10:217
- Ann Transl Med, 2020 8(7):451
- Onco Targets Ther, 2020 13:5721-5729
- Onco Targets Ther, 2020 1;13:2711-2723
- J Cancer, 2020 11(21):6234-6242
- BMC Complement Med Ther, 2020 20(1):13
- Acta Diabetol, 2020 10.1007/s00592-020-01582-w
- Int J Immunopathol Pharmacol, 2020 Dec;34:2058738420909041
- Cancer Manag Res, 2020 12:8081-8091
- Innate Immun, 2020 1753425920942580
- Biochem Biophys Res Commun, 2020 522(2):518-524
- J Recept Signal Transduct Res, 2020 1-11
- Can J Physiol Pharmacol, 2020 10.1139/cjpp-2020-0280
- Nat Commun, 2019 10(1):5720
- Neuron, 2019 101(1):32-44
- Cell Death Dis, 2019 10(4):307
- Acta Pharmacol Sin, 2019 10.1038/s41401-019-0220-1
- Biochem Pharmacol, 2019 170:113660
- J Nutr Biochem, 2019 69:108-119
- J Cell Physiol, 2019 10.1002/jcp.28810
- J Cell Mol Med, 2019 10.1111/jcmm.14551
- Sci Rep, 2019 9(1):3392
- Biomed Res Int, 2019 2019:7587451
- Exp Ther Med, 2019 18(5):3801-3808
- Nan Fang Yi Ke Da Xue Xue Bao, 2019
- J Exp Clin Cancer Res, 2018 37(1):41
- EBioMedicine, 2018 34:35-45
- Cell Death Dis, 2018 9(3):376
- Biomed Pharmacother, 2018 10.1016/j.biopha.2018.03.126
- Life Sci, 2018 207:451-460
- Life Sci, 2018 211:133-139
- iScience, 2018 3:87-101
- Front Pharmacol, 2018 9:210
- Front Pharmacol, 2018 9:1046
- Front Cell Neurosci, 2018 12:437
- Cell Physiol Biochem, 2018 48(6):2456-2469
- Int J Med Sci, 2018 15(14):1648-1657
- Toxicol Lett, 2018 288:35-43
- Med Sci Monit, 2018 24:5391-5397
- Biochem Biophys Res Commun, 2018 497(2):535-542
- Biochem Biophys Res Commun, 2018 503(4):2792-2799
- J Tradit Chin Med, 2018 38(4):556-561
- J Surg Res, 2018 231:116-125
- Theranostics, 2017 7(3):733-750
- J Exp Clin Cancer Res, 2017 36(1):105
- J Mater Chem B, 2017 5(25):5009-5018
- Genome Res, 2017 27(6):1087-1097
- Biochim Biophys Acta Mol Basis Dis, 2017 1863(11):2848-2861
- Oncotarget, 2017 8(50):88043-88058
- Oncotarget, 2017 8(21):34258-34267
- Oncotarget, 2017 8(44):76783-76796
- Oncotarget, 2017 8(9):14978-14987
- Oncotarget, 2017 9(16):12639-12648
- Oncotarget, 2017 10.18632/oncotarget.16075
- Int J Oncol, 2017 50(6):2000-2010
- RSC Advances, 2017 10.1039/C7RA02113E
- J Cancer Res Clin Oncol, 2017 143(5):793-805
- Mol Biosyst, 2017 13(10):1993-2005
- Oncotarget, 2016 7(37):60123-60132
化学信息&溶解度
分子量 | 364.78 |
分子式 | C17H17ClN2O5 |
CAS号 | 305834-79-1 |
Smiles | CCOC(=O)C1=C(OC2=C(C1C(C#N)C(=O)OCC)C=C(C=C2)Cl)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 73 mg/mL ( 200.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 36 mg/mL Water : Insoluble DMSO : 72 mg/mL ( 197.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 72 mg/mL Water : Insoluble DMSO : 72 mg/mL ( 197.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 72 mg/mL Water : Insoluble DMSO : 72 mg/mL ( 197.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 72 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:3.6mg/ml
(9.87mM)
操作示例:以 1 mL 工作液为例,取50μL72mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。